Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20991255 | 0.87 | TSHR (0.34) | NPSR1TSHRGAAUSP2TP53 | |
| SCHEMBL21082154 | 0.82 | NPSR1 (0.33) | NPSR1TSHRGAAUSP2TP53 | |
| SCHEMBL16980288 | 0.81 | TSHR (0.33) | NPSR1TSHRGAATP53MEN1 | |
| SCHEMBL24440155 | 0.81 | TSHR (0.33) | NPSR1TSHRGAATP53POLB | |
| SCHEMBL20215065 | 0.79 | HSD17B3 (0.47) | — | |
| SCHEMBL24974795 | 0.79 | MAP3K5 (0.32) | NPSR1TSHRGAAUSP2TP53 | |
| SCHEMBL19604395 | 0.78 | HSD17B3 (0.35) | NPSR1TSHR | |
| SCHEMBL25979383 | 0.78 | TSHR (0.31) | NPSR1TSHRPOLB | |
| SCHEMBL20991239 | 0.78 | MEN1 (0.32) | NPSR1TSHRTP53MEN1CYP3A4 | |
| SCHEMBL14296207 | 0.77 | KMT2A (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224329-A1 | Incremental Dose Finding in Controlled-Release PTH Compounds | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224329-A1 | Incremental Dose Finding in Controlled-Release PTH Compounds | PTH1R, CALCA, CALCB | NPSR1 371/4885TSHR 284/4885GAA 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.